Hear from this leading panel of Australian medical oncologists who review and analyse three practice-shaping European Society of Medical Oncology (ESMO) prostate cancer presentations, the PEACE-1 study, the ARCHES study and the STAMPEDE trial (M0 cohort)
In this video, our experts debate the role of earlier integration of intensified systemic therapy in clinical trials and how this may translate into changes of clinical practice, to achieve better outcomes for men with prostate cancer.
The PEACE-1 trial tested the combination of standard of care +/- abiraterone in M1 hormone-sensitive prostate cancer on conventional imaging. Outcomes in patients treated with ADT + Docetaxel as part of standard of care are discussed, including for which group of patients triple therapy could become a new standard of care.
The ARCHES study examines the effect of ADT +/- enzalutamide in M1 hormone-sensitive prostate cancer. The faculty discusses the reported overall survival data and subgroups supporting the use of enzalutamide.
Our experts’ discussion on the STAMPEDE trial (M0) focuses on high-risk nonmetastatic hormone-sensitive prostate cancer.
This program is proudly supported by Astellas.